Open AccessEfficacy Of Gonadotropin‐Releasing Hormone Agonist (Buserelin) in The Treatment Of Endometriosis
Author(s) -
Rönnberg Lars,
Koskimies Aarne,
Laatikainen Timo,
Ranta Tapio,
Saastamoinen Jukka
Publication year - 1989
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016348909087689
Subject(s) - buserelin , medicine , endometriosis , gonadotropin releasing hormone agonist , agonist , gynecology , gonadotropin releasing hormone , estrogen , hormone , luteinizing hormone , receptor
In a multi center study, the efficacy of and tolerance of 6 months' intranasal gonadotropin‐releasing hormone agonist (buserelin) treatment (300 μg × 3/day) on laparoscopically verified endometriosis was evaluated in 25 patients. At second‐look laparoscopy at the end of medication, the mean endometriosis score had fallen by 82.2%. All endometriosis‐associated symptoms and physical findings decreased or almost disappeared during buserelin administration. After discontinuing therapy, they showed a tendency to reappear, but nevertheless they were milder after one year of follow‐up, than before treatment. Seven (54%) of the 13 women wishing pregnancy actually conceived. Vaginal irregular spotting bleedings during the first 2 months occurred in 7 patients. No patient withdrew from the trial because of side effects, although almost all women developed symptoms of estrogen deficiency (serum estradiol concentrations fell to menopausal levels).